Recent Updates in Opioid Use Disorder Treatment-View Presentation

Video Transcription

Video Summary

The webinar focused on two extended-release buprenorphine formulations and their efficacy in treating opioid use disorder. The first formulation, Sublocade, was studied in a trial comparing two dosing strategies: monthly doses of 300mg versus two months of 300mg followed by four months of 100mg. The study found that both dosing strategies were more efficacious than placebo in terms of abstinence weeks and retention. The second formulation, Brixadi, was studied in a trial comparing weekly doses for three months followed by monthly doses for three months to daily sublingual buprenorphine. The study showed that the extended-release formulation was non-inferior to sublingual buprenorphine on the primary outcome of abstinence weeks and had higher rates of abstinence and responder status. Both formulations showed promising results and were generally well-tolerated. However, more research is needed to determine the role of these formulations in real-world settings and in patient populations with specific needs, such as those who may benefit from sublingual supplementation or home delivery of the injections. It's important to note that the availability and access to these formulations may be subject to regulatory considerations and may require specific ordering and delivery processes.

Keywords

extended-release buprenorphine formulations

efficacy

opioid use disorder

Sublocade

dosing strategies

abstinence weeks

Brixadi

sublingual buprenorphine

responder status

real-world settings

delivery processes